Last year, we interviewed semi-pro tennis player Josh Golding and he has been in touch to talk to use about his progress with tennis and diabetes. He told us, “I have now been involved with a local radio station in Milton Keynes, MKFM, read more »

Entries for the Quality in Care Awards 2019 are now open. The deadline for submitting nominations is 31 May. If you know of someone who’s doing a great job in the arena of diabetes care, then simply get an entry form, fill it read more »

Within the next six months, Animas users need to be transitioned onto another pump of their choice. As previously advised, Animas’ goal is to transition all patients globally to another insulin delivery system and exit the market fully by September 2019. Animas is read more »

The European Commission (EC) has approved Forxiga (dapagliflozin) for use in Type 1 diabetes (T1D) as an adjunct to insulin in patients with a BMI greater than 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. read more »

Type 1 diabetic Rob Brown has set off for Morocco where he is taking part in the Marathon des Sables, a 150-mile footrace across the Sahara Desert. He says, “I’ve had diabetes since I was 13. Managing the condition is a constant read more »

Novo Nordisk UK has announced that Ozempic (semaglutide), a new once-weekly GLP-1 analogue injection for the treatment of Type 2 diabetes is now available in the UK. Ozempic works by mimicking the function of the GLP-1 (human glucagon-like peptide-1) hormone produced in the read more »

One in ten people over 40 in the UK is now living with a diagnosis of Type 2 diabetes, according to new analysis released by Diabetes UK. The new figures show that there are 3.8 million people living with a diagnosis of read more »

Marking the start of NHS England’s Type 2 Diabetes Prevention Week, Diabetes UK has released new analysis which shows that one person is diagnosed with Type 2 diabetes every three minutes in England and Wales. With just over two hundred thousand people read more »

The administrators appointed at Cellnovo Ltd., the Cellnovo Group (“Cellnovo” or the “Company”)’s UK subsidiary, have concluded an initial analysis and have actioned a restructuring plan to focus all activities on identifying strategic partners and financial investors. As a result, a core read more »

Those of us on insulin pumps must wait four years between each pump change, but Animas users were forced to change sooner than that when the company announced it was retreating from the market. Final choices need to be made by the read more »